Patent Picks: What "Modified Collagen," Cyclodextrin UV Screens, and Fatty Acid Actives Actually Mean by Dose and Formulation

Cosmetics & Toiletries' latest "Patent Picks" column groups three unrelated filings under one headline: a modified collagen, a cyclodextrin-based UV/IR screen, and a fatty acid anti-inflammatory. The column, curated by editor Rachel Grabenhofer from public patent databases, is a digest rather than an evaluation, and it does not test whether the claims inside a filing hold up in a finished formula. A granted or published patent is also not a marketed product. What is worth doing with a list like this is reading each pick against the broader ingredient class it belongs to, because source, concentration, and delivery form determine whether a claim like "modified" or "anti-inflammatory" describes something new or something the industry has sold under the same name for years.

"Modified collagen" is doing a lot of work as a phrase this year. For decades it has meant chemically altered collagen, peptides acetylated, phosphorylated, or conjugated to actives such as retinol to improve solubility, skin penetration, or shelf stability. Advanced Collagen Science's acetylated collagen patents sit in that older track: the collagen backbone is conventional, and the modification is a targeted chemical change meant to boost performance at use levels the category has relied on for years. That is a different technology generation from the collagen story dominating trade press this year. In April, BASF and Bota Biosciences launched SkinNexus Collag3n, described as a human-identical recombinant Collagen III fragment produced by yeast fermentation, alongside a companion active called NeoHelix Regenerate, according to BASF. Geltor sells a biodesigned vegan marine collagen under the Collume name, and HTL Biotechnique acquired Modern Meadow's recombinant collagen platform in 2024. Whether a freshly filed "modified collagen" patent belongs to the older chemical-modification lineage or the newer precision-fermentation wave changes the commercial story: sustainability and animal-free sourcing on one side, incremental potency gains on the other. The word alone does not tell you which.

The cyclodextrin pick sits on more established ground than the framing suggests. Cyclodextrins have been used in cosmetics for years as complexation agents, mainly to control odor and to stabilize UV filters like avobenzone against photodegradation. A prior patent, US10485748, already claims alpha, beta, and gamma cyclodextrin as a physical UV and IR radiation screen intended to reduce or replace metal-oxide blockers such as titanium dioxide and zinc oxide, while also stabilizing chemical filters formulated alongside it. That distinction between cyclodextrin as an encapsulation aid and cyclodextrin as the screening agent itself is the difference between a supporting ingredient and a functional sunscreen active, and it changes how much of it a formula needs to make an SPF claim.

The physical-screen framing also lands inside a live regulatory argument. The FDA currently recognizes only zinc oxide and titanium dioxide as generally recognized as safe and effective for sunscreen, after a 2020 agency study raised questions about systemic absorption of several chemical UV filters. In the EU, regulators have moved to cap octocrylene and have already prohibited 4-MBC (enzacamene) from sale starting in May 2026. Encapsulation and complexation chemistry, cyclodextrin included, is one of the few formulation routes that lets a brand keep photostability benefits while reducing reliance on the filters facing the most scrutiny on both sides of the Atlantic. A patent claiming cyclodextrin as a screening agent in its own right, rather than just a stabilizer, is worth watching for that reason even before it reaches a shelf.

Fatty acids as anti-inflammatory actives are the least novel-sounding of the three picks, and the prior art bears that out. US9750725B2, "Fatty acids as anti-inflammatory agents," and the older US6280755 on non-methylene-interrupted fatty acids both cover this territory, as does US5208012, "Anti-inflammatory or anti-sunburn cosmetic composition." Any new filing in this space is competing with three decades of prior claims, so the interesting question is what specific fatty acid, chain length, or delivery vehicle it adds, not whether fatty acids calm inflamed skin in general. A December 2025 systematic review in PMC, covering specialized pro-resolving lipid mediators and dietary omega-3 and omega-6 fatty acids in inflammatory skin disease, is a more current anchor for the mechanism than any single patent filing: it traces how the ratio and downstream metabolites of these fatty acids, not just their presence, drive the resolution of inflammation rather than merely suppressing it.

That ratio-dependent mechanism is the detail a patent abstract rarely spells out, and it is also the reason concentration and sourcing matter more than the ingredient name on a label. An omega-6-heavy formulation and an omega-3-heavy one can produce different inflammatory outcomes at the same total fatty acid percentage, which is exactly the kind of formulation-level nuance that separates a patent claim from a working product.